<p>Total number (×10<sup>3</sup> cells/µl blood) of lymphocytes, T cells and B cells in treatment-naive, IFN-β treated MS patients at baseline and fingolimod-treated MS patients during 12 months follow-up. Mean and standard error of the mean are presented. • lymphocytes; ▪ CD4<sup>+</sup> T cells; ▴ CD19<sup>+</sup> B cells.</p
Objective:Fingolimod is approved for the treatment of highly active relapsing remitting multiple scl...
<p>Concentration of CD26 defined CD4<sup>+</sup> T-cell and CD8<sup>+</sup> T-cell subsets in the bl...
<p>Concentration of (A) CD161<sup>NEG</sup> and CD161<sup>POS</sup> CD4<sup>+</sup> T-cells and (E) ...
<p>(A) CD19<sup>+</sup> B cell subtype proportion and (B) CD4<sup>+</sup> T cell subtype proportion ...
<p>PBMCs of MS patients before (t0, n = 16) or after three months of treatment by fingolimod (t3, n ...
<p>The median and range are shown. Lymphoid cells were gated according to their FSC/SSC profile.</p>...
<p>Effects of fingolimod on peripheral blood lymphocyte counts (A) and absolute numbers and percenta...
<p>p<0.01 is considered statistically significant. Comparisons are pairwise. Bars show mean values, ...
<p>Effects of fingolimod on IFNγ- (A), IL17- (B), IL9- (C), and IL4-producing (D) cells in CD4<sup>+...
During a period of 30 months, we studied the proportions of B and T cells, and of T cell subpopulati...
<div><p>Background and objective</p><p>The long term effects of fingolimod, an oral treatment for re...
<p>Effects of fingolimod on phenotypically distinct CD4<sup>+</sup>T (A) and CD8<sup>+</sup>T (B) ce...
<p>p<0.01 is considered statistically significant. Comparisons are pairwise. Bars show mean values, ...
Objective: To establish cytometry profiles associated with disease stages and immunotherapy in MS. M...
We investigated, lymphocyte count (LC) and lymphocyte subpopulations (LS) in a real life setting of ...
Objective:Fingolimod is approved for the treatment of highly active relapsing remitting multiple scl...
<p>Concentration of CD26 defined CD4<sup>+</sup> T-cell and CD8<sup>+</sup> T-cell subsets in the bl...
<p>Concentration of (A) CD161<sup>NEG</sup> and CD161<sup>POS</sup> CD4<sup>+</sup> T-cells and (E) ...
<p>(A) CD19<sup>+</sup> B cell subtype proportion and (B) CD4<sup>+</sup> T cell subtype proportion ...
<p>PBMCs of MS patients before (t0, n = 16) or after three months of treatment by fingolimod (t3, n ...
<p>The median and range are shown. Lymphoid cells were gated according to their FSC/SSC profile.</p>...
<p>Effects of fingolimod on peripheral blood lymphocyte counts (A) and absolute numbers and percenta...
<p>p<0.01 is considered statistically significant. Comparisons are pairwise. Bars show mean values, ...
<p>Effects of fingolimod on IFNγ- (A), IL17- (B), IL9- (C), and IL4-producing (D) cells in CD4<sup>+...
During a period of 30 months, we studied the proportions of B and T cells, and of T cell subpopulati...
<div><p>Background and objective</p><p>The long term effects of fingolimod, an oral treatment for re...
<p>Effects of fingolimod on phenotypically distinct CD4<sup>+</sup>T (A) and CD8<sup>+</sup>T (B) ce...
<p>p<0.01 is considered statistically significant. Comparisons are pairwise. Bars show mean values, ...
Objective: To establish cytometry profiles associated with disease stages and immunotherapy in MS. M...
We investigated, lymphocyte count (LC) and lymphocyte subpopulations (LS) in a real life setting of ...
Objective:Fingolimod is approved for the treatment of highly active relapsing remitting multiple scl...
<p>Concentration of CD26 defined CD4<sup>+</sup> T-cell and CD8<sup>+</sup> T-cell subsets in the bl...
<p>Concentration of (A) CD161<sup>NEG</sup> and CD161<sup>POS</sup> CD4<sup>+</sup> T-cells and (E) ...